Sort   by:  
 Page size 
UnknownEffective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd).
Not available
S-EPMC11965298 | biostudies-literature
UnknownSystemic Lupus Erythematosus and Mortality in Elderly Patients With Early Breast Cancer.
Not available
S-EPMC12019812 | biostudies-literature
UnknownA comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer Study.
Not available
S-EPMC12325588 | biostudies-literature
UnknownTranscriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.
Not available
S-EPMC9234971 | biostudies-literature
UnknownTrends in the use of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and recently diagnosed colorectal, lung, or prostate cancer.
Not available
S-EPMC11822753 | biostudies-literature
UnknownStimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.
Not available
S-EPMC7483405 | biostudies-literature
UnknownAPOBEC3 enzymes mediate efficacy of cisplatin and are epistatic with base excision repair and mismatch repair in platinum response.
Not available
S-EPMC7646253 | biostudies-literature
UnknownFunctional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.
Not available
S-EPMC6171747 | biostudies-literature
UnknownLoss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.
Not available
S-EPMC5733075 | biostudies-literature
UnknownKinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.
Not available
S-EPMC10543968 | biostudies-literature
Sort   by:  
 Page size